Endoscopic ultrasonography-guided celiac plexus neurolysis in patients with unresectable pancreatic cancer: An update

dc.contributor.authorPerez-Aguado, Guillermo
dc.contributor.authorde la Mata, Diego Martinez-Acitores
dc.contributor.authorValenciano, Carlos Marra-Lopez
dc.contributor.authorSainz, Ignacio Fernandez-Urien
dc.contributor.authoraffiliation[Perez-Aguado, Guillermo] Complejo Hosp Insular Materno Infantil Gran Canar, Dept Gastroenterol, Ave Maritima Sur S-N, Las Palmas Gran Canaria 35016, Las Palmas, Spain
dc.contributor.authoraffiliation[de la Mata, Diego Martinez-Acitores] Complejo Hosp Navarra CHN, Endoscopy Unit, Dept Gastroenterol, Navarra 31008, Spain
dc.contributor.authoraffiliation[Sainz, Ignacio Fernandez-Urien] Complejo Hosp Navarra CHN, Endoscopy Unit, Dept Gastroenterol, Navarra 31008, Spain
dc.contributor.authoraffiliation[Valenciano, Carlos Marra-Lopez] Agencia Sanitaria Costa Sol, Endoscopy Unit, Dept Gastroenterol, Malaga 29603, Spain
dc.date.accessioned2025-01-07T14:57:08Z
dc.date.available2025-01-07T14:57:08Z
dc.date.issued2021-10-16
dc.description.abstractPancreatic cancer produces disabling abdominal pain, and the pain medical management for pancreatic cancer is often challenging because it mainly relies on the use of narcotics (major opioids). However, opioids often provide suboptimal pain relief, and the use of opioids can lead to patient tolerance and several side effects that considerably reduce the quality of life of pancreatic cancer patients. Endosonography-guided celiac plexus neurolysis (EUS-CPN) is an alternative for pain control in patients with nonsurgical pancreatic cancer; EUS-CPN consists of the injection of alcohol and a local anesthetic into the area of the celiac plexus to achieve chemical ablation of the nerve tissue. EUS-CPN via the transgastric approach is a safer and more accessible technique than the percutaneous approach. We have reviewed most of the studies that evaluate the efficacy of EUS-CPN and that have compared the different approaches that have been performed by endosonographers. The efficacy of EUS-CPN varies from 50% to 94% in the different studies, and EUS-CPN has a pain relief duration of 4-8 wk. Several factors are involved in its efficacy, such as the onset of pain, previous use of chemotherapy, presence of metastatic disease, EUS-CPN technique, type of needle or neurolytic agent used, etc. According to this review, injection into the ganglia may be the best technique, and a good visualization of the ganglia is the best predictor for a good EUS-CPN response, although more studies are needed. However, any of the 4 different techniques could be used to perform EUS-CPN effectively with no differences in terms of complications between the techniques, but more studies are needed. The effect of EUS-CPN on pain improvement, patient survival and patient quality of life should be evaluated in well-designed randomized clinical trials. Further research also needs to be performed to clarify the best time frame in performing a EUS-CPN.
dc.identifier.doi10.4253/wjge.v13.i10.460
dc.identifier.issn1948-5190
dc.identifier.pmid34733407
dc.identifier.unpaywallURLhttps://doi.org/10.4253/wjge.v13.i10.460
dc.identifier.urihttps://hdl.handle.net/10668/26752
dc.identifier.wosID713675800002
dc.issue.number10
dc.journal.titleWorld journal of gastrointestinal endoscopy
dc.journal.titleabbreviationWorld j. gastrointest. endosc.
dc.language.isoen
dc.organizationSAS - Hospital Costa del Sol
dc.publisherBaishideng publishing group inc
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectPancreatic cancer
dc.subjectEndosonography
dc.subjectCeliac plexus neurolysis
dc.subjectOpioids
dc.subjectEchoendoscopy
dc.subjectSpinal-cord infarction
dc.subjectGanglia neurolysis
dc.subjectPain management
dc.subjectEfficacy
dc.subjectComplication
dc.subjectIschemia
dc.subjectRelief
dc.subjectBlock
dc.titleEndoscopic ultrasonography-guided celiac plexus neurolysis in patients with unresectable pancreatic cancer: An update
dc.typereview
dc.type.hasVersionVoR
dc.volume.number13
dc.wostypeReview

Files